- U.S. Patent Trial and Appeal Board revoked central claims of U.S. Patent 11,435,360 in inter partes review IPR2024-01473.
- Patent is owned by Brigham and Women’s Hospital, with exclusive license held by Seer.
- Decision struck down sole independent Claim 1 covering certain nanoparticle-based protein detection workflows.
- PreOmics, Biognosys framed ruling as validation that key concepts were already disclosed in scientific literature.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.
Comments